Engineering pharma innovation

07 September 2017 | General News
Printer Friendly and PDF
NUS Engineering Professor Victor Shim, Vice-Dean (External Relations & Outreach) (1st from right), was the NUS signatory for the signing of the MOU, witnessed by Mr Iswaran (3rd from right) and A*STAR Chairman Mr Lim Chuan Poh (3rd from left) (Photo: A*STAR)

The Agency for Science, Technology and Research (A*STAR) and NUS Engineering have inked a Memorandum of Understanding (MOU) with leading pharmaceutical companies GSK, MSD International, and Pfizer Asia Pacific to establish the Pharma Innovation Programme Singapore (PIPS) on 5 September.

The partners will explore collaboration on pharma manufacturing technologies, supply chain management and operations.

NUS Engineering Dean Professor Chua Kee Chaing said, “This unique collaboration will foster a sustainable ecosystem in which innovation, skills training, entrepreneurship and employment are seamlessly integrated to benefit Singapore and the wider society. We look forward to working closely with our partners to accelerate the growth and development of the pharmaceutical manufacturing industry.” Prof Chua also highlighted NUS Engineering’s expertise in continuous pharmaceutical manufacturing and biocatalysis technology, and its longstanding ties with the industry.

The MOU was signed at the inaugural Future of Manufacturing Summit, a platform for global thought leaders in manufacturing to discuss key technological trends driving factories in the future. The ceremony was witnessed by Mr S Iswaran, Minister for Trade and Industry (Industry), who was attending the Summit as its Guest-of-Honour.

This unique collaboration will foster a sustainable ecosystem in which innovation, skills training, entrepreneurship and employment are seamlessly integrated to benefit Singapore and the wider society.

In his speech at the Summit, Mr Iswaran spoke about the government’s commitment to supporting the development of advanced manufacturing technologies in Singapore to ensure that the sector stays competitive. The vision for PIPS, he said, “is for Singapore to lead the way in the global transformation of pharmaceutical manufacturing to create unique value for patients, the pharmaceutical industry and for Singapore”.

See media coverage.